# US 2012/0252833 A1 · Sustained-release product comprising a combination of a non-opioid amine and a non-steriodal anti-inflammatory drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252833 A1
- Document ID: US20120252833A1
- Status: Published application
- Kind: A1
- Application number: 13/496,818
- Filed: 2009-12-31
- Published: 2012-10-04
- Earliest claimed: 2009-09-17
- Assignees: Upsher-Smith Laboratories, Inc.
- Inventors: Christian F. Wertz; James S. Jensen; Victoria Ann O'Neill; Sean B. Mahoney; Stephen M. Berge
- Web page: https://patentgrep.com/patent/US20120252833A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 11/14: Antitussive agents
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.

## Claims

### Claim 1

A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix;
a therapeutically effective amount of a non-opioid amine-containing compound; and
a salt of a non-steroidal anti-inflammatory drug (NSAID);
wherein the amine-containing compound and the salt of an NSAID are within the hydrophilic matrix; and
wherein the composition exhibits a release profile of the amine-containing compound comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.

### Claim 2

A sustained-release oral pharmaceutical composition comprising within a single dosage faun:
a hydrophilic matrix;
a therapeutically effective amount of a non-opioid amine-containing compound;
a salt of a non-steroidal anti-inflammatory drug (NSAID); and
a pharmaceutically acceptable anionic surfactant;
wherein the amine-containing compound, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.

### Claim 3 (depends on 2)

The composition of claim 2 which exhibits a release profile of the amine-containing compound comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the amine group comprises a secondary amine, a tertiary amine, a primary amine, or combination thereof.

### Claim 5 (depends on 3)

The composition of claim 3 wherein the amine-containing compound comprises a tertiary amine.

### Claim 6 (depends on 2)

The composition of claim 2 wherein the amine-containing compound is selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, baclofen, arbaclofen, ritodrine, tizanidine, flurazepam, chlorpheniramine, doxylamine, diphenhydramine, diltiazem, rimantadine, amantadine, memantine, and combinations thereof.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the amine-containing compound is a salt comprising a hydrochloride, a bitartrate, an acetate, a naphthylate, a tosylate, a mesylate, a besylate, a succinate, a palmitate, a stearate, an oleate, a pamoate, a laurate, a valerate, a hydrobromide, a sulfate, a methane sulfonate, a tartrate, a citrate, a maleate, or a combination of the foregoing.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the NSAID salt is selected from the group consisting of a salicylate derivative, a 2-aryl propionic acid derivative, a pyrazolidine derivative, an N-arylanthranilic acid derivative, an oxicam derivative, an arylalkanoic acid, an indole derivative, and combinations thereof.

### Claim 9 (depends on 2)

The composition of claim 2, as they depend on claim 2, wherein the pharmaceutically acceptable anionic surfactant is selected from the group consisting of monovalent alkyl carboxylates, acyl lactylates, alkyl ether carboxylates, N-acyl sarcosinates, polyvalent alkyl carbonates, N-acyl glutamates, fatty acid-polypeptide condensates, sulfur-containing surfactants, phosphated ethoxylated alcohols, and combinations thereof.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the NSAID salt is present in an amount effective to provide zero-order release kinetics under in vitro conditions.

### Claim 11 (depends on 2)

The composition of claim 2 wherein the pharmaceutically acceptable anionic surfactant is present in a release-modifying amount.

### Claim 12 (depends on 1)

The composition of claim 1 wherein the single dosage form is a tablet form.

### Claim 13 (depends on 1)

The composition of claim 1 wherein the hydrophilic matrix comprises at least one hydrophilic polymeric compound selected from the group consisting of a gum, a cellulose ether, an acrylic resin, a polyvinyl pyrrolidone, a protein-derived compound, and combinations thereof.

### Claim 14

A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix;
a therapeutically effective amount of an amine-containing compound selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, ritodrine, memantine, amantadine, salts thereof, and combinations thereof; and
a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof;
wherein the amine-containing compound and the salt of an NSAID are within the hydrophilic matrix; and
wherein the composition exhibits a release profile of the amine-containing compound comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.

### Claim 15

A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix;
a therapeutically effective amount of an amine-containing compound selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, ritodrine, memantine, amantadine, salts thereof, and combinations thereof;
a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof; and
a pharmaceutically acceptable anionic surfactant selected from the group consisting of sodium lauryl sulfate, docusate sodium, docusate calcium, and combinations thereof;
wherein the amine-containing compound the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.

### Claim 16 (depends on 15)

The composition of claim 15 which exhibits a release profile of the amine-containing compound comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.

### Claim 17 (depends on 1)

A method of providing a desired effect in a subject, the method comprising administering to a subject a composition of claim 1.

### Claim 18 (depends on 17)

The method of claim 17 wherein administering the composition comprises administering once or twice per day.

### Claim 19 (depends on 18)

The method of claim 18 wherein administering the composition comprises administering once per day.
